The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein
S. Piacentini, A. Riccio, S. Santopolo, S. Pauciullo, S. La Frazia, A. Rossi, J.-F. Rossignol, M. G. Santoro
The paper shows nitazoxanide inhibits seasonal coronaviruses by interfering with spike glycoprotein maturation, not affecting viral entry.
bioRxiv · Jul 13, 2022 · PreprintMicrobiology